FrancophonIA/ELRC3.0 huggingface dataset:
English: Prolonged erections
Slovenian: Bolnike z erekcijami, ki trajajo
English: Phadisco Ltd
Slovenian: Produtos Farmacêuticos, Lda.
English: Excipient with known effect:
Slovenian: Redko so poročali o neželenih učinkih:
English: Facial oedema,
Slovenian: Bolezni sečil hematurija
English: Gastrointestinal disorders Nausea,
Slovenian: Bolniki z znano dedno degenerativno okvaro očesne mrežnice,
English: Placebo was not effective in any of the patients.
Slovenian: Placebo ni bil učinkovit pri nobenemu bolniku.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Krystexxa on 8 January 2013.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Krystexxa, veljavno po vsej Evropski uniji, odobrila dne 8. januarja 2013.
English: The full EPAR for Krystexxa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Krystexxa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Although there may be serious side effects (such as infusion reactions and gout flares) these were considered manageable.
Slovenian: Čeprav lahko pride do resnih neželenih učinkov (kot so reakcije na infundiranje in napadi protina), so bili ti ocenjeni kot obvladljivi.
English: The company that makes Krystexxa will carry out a study of the long-term safety of the medicine, including its safety and effectiveness in patients who stop treatment and later restart it.
Slovenian: Družba, ki proizvaja zdravilo Krystexxa, bo izvedla študijo o dolgoročni varnosti tega zdravila, vključno z varnostjo in učinkovitostjo pri bolnikih, ki prenehajo z zdravljenjem in kasneje ponovno začnejo z njim.
English: This is a summary of the European public assessment report (EPAR) for Krystexxa.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Krystexxa.
English: This lowers the levels of uric acid in the blood.
Slovenian: To znižuje ravni sečne kisline v krvi.
English: Krystexxa pegloticase
Slovenian: Krystexxa peglotikaza
English: To reduce the risk of these reactions, patients are given other medicines before treatment with Krystexxa.
Slovenian: Da bi zmanjšali tveganje teh reakcij, bolniki pred zdravljenjem z zdravilom Krystexxa prejmejo tudi druga zdravila.
English: Reactions are more common in patients who develop antibodies (proteins produced by the immune system, the body's natural defences) that reduce the effect of the treatment.
Slovenian: Reakcije so pogostejše pri bolnikih, ki razvijejo protitelesa (beljakovine, ki jih proizvede imunski sistem, naravni obrambni sistem telesa), ki zmanjšajo učinek zdravljenja.
English: Overall, 42% of patients (36 out of 85) given the medicine every two weeks showed a persistent response; the figure for those given Krystexxa every four weeks was 35% (29 out of 84).
Slovenian: Skupaj je 42 % bolnikov (36 od 85), ki so prejemali zdravilo Krystexxa vsaka dva tedna, izkazalo dolgotrajen odziv na zdravljenje; pri tistih, ki so zdravilo Krystexxa prejemali vsake štiri tedne, je ta delež znašal 35 % (29 od 84).
English: The effects of Krystexxa were first tested in experimental models before being studied in humans.
Slovenian: Učinki zdravila Krystexxa so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
English: For more information about treatment with Krystexxa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Krystexxa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Although uric acid levels were quickly lowered by Krystexxa, its effect was reduced within a few weeks in more than half the patients.
Slovenian: Čeprav je zdravilo Krystexxa hitro znižalo ravni sečne kisline, se je ta učinek v nekaj tednih zmanjšal pri več kot polovici bolnikov.
English: What measures are being taken to ensure the safe use of Krystexxa?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Krystexxa?
English: The main measure of effectiveness was the number of patients who showed a persistent response to the treatment, defined as uric acid level in the blood below 6 mg/dl for at least 80% of the time during both the third and sixth months of the study.
Slovenian: Glavno merilo učinkovitosti je bilo število bolnikov, ki so izkazali dolgotrajen odziv na zdravljenje, opredeljen kot znižanje ravni sečne kisline v krvi pod 6 mg/dl v vsaj 80 % časa med tretjim in med šestim mesecem študije.
English: The CHMP therefore decided that Krystexxa's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zato zaključil, da so koristi zdravila Krystexxa večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: The most common serious side effects with Krystexxa are anaphylaxis (a severe allergic reaction), seen in about 7 patients in 100, infusion reactions (including flushing, skin rashes, itching, sweating, chest pain, difficulty in breathing, chills, and raised blood pressure), seen in about 26 patients in 100, and gout flares (worsening of gout symptoms) which were more common in the first 3 months of treatment.
Slovenian: Najpogostejši resni neželeni učinki zdravila Krystexxa so anafilaksija (huda alergijska reakcija), opažena pri približno 7 bolnikih od 100, reakcije na infundiranje (vključno z zardevanjem, kožnimi izpuščaji, srbenjem, potenjem, bolečinami v prsnem košu, težavami z dihanjem, mrzlico in povišanim krvnim tlakom), opažene pri približno 26 bolnikih od 100 in napadi protina (poslabšanje simptomov protina), ki so bili pogostejši v prvih treh mesecih zdravljenja.
English: All patients are monitored for any reactions during the infusion and for at least one hour afterwards.
Slovenian: Pri vseh bolnikih je treba preverjati, ali med infundiranjem in še najmanj eno uro po njem morebiti ni prišlo do pojava kakršnih koli reakcij.
English: Other information about Krystexxa
Slovenian: Druge informacije o zdravilu Krystexxa
English: Krystexxa, given at a dose of 8 mg every two or four weeks, was compared with placebo (a dummy treatment), over a period of six months.
Slovenian: Zdravilo Krystexxa, dano v odmerku 8 mg vsake dva ali štiri tedne, so primerjali s placebom (zdravilom brez zdravilne učinkovine) v obdobju šestih mesecev.
English: Krystexxa is used to treat adult patients with severe chronic (long-term) tophaceous gout.
Slovenian: Zdravilo Krystexxa se uporablja za zdravljenje odraslih bolnikov s hudim kroničnim (dolgotrajnim) protinom s tofi.
English: Krystexxa must not be used in people who are hypersensitive (allergic) to pegloticase or any of the other ingredients, and in people with a rare blood disorder called glucose 6-phosphate dehydrogenase (G6PD) deficiency (favism) or similar disorders.
Slovenian: Zdravila Krystexxa ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) peglotikazo ali katero koli drugo sestavino zdravila, in osebe z redko krvno motnjo, imenovano pomanjkanje glukoza6-fosfat dehidrogenaze (G6PD) (favizem), ali podobnimi motnjami.
English: This is where high levels of the substance uric acid develop in the blood and then crystallise in joints and tissues, forming tophi (stones) that cause pain and joint damage.
Slovenian: To je bolezen, pri kateri se v krvi razvijejo visoke ravni sečne kisline, ki nato kristalizira v sklepih in tkivih ter oblikujejo tofe (kamne), ki povzročajo bolečino v sklepih in njihovo poškodbo.
English: The uricase in Krystexxa is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce uricase.
Slovenian: Urikaza v zdravilu Krystexxa se proizvaja z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri bakterija prejme gen (DNK), s katerim lahko tvoriti urikazo.
English: What benefit has Krystexxa shown during the studies?
Slovenian: Kakšne koristi je zdravilo Krystexxa izkazalo med študijami?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Krystexxa.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Krystexxa, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Treatment with Krystexxa should be given under the supervision of a doctor who has experience in the treatment of severe chronic gout, in a setting where facilities for resuscitation are available.
Slovenian: Zdravljenje z zdravilom Krystexxa je treba izvajati pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem hudega kroničnega protina, in v okolju, kjer je na voljo oprema za oživljanje.
English: Uricase breaks down uric acid into another substance, allantoin, which can be passed out of the body in the urine.
Slovenian: Urikaza sečno kislino razgradi v drugo snov, imenovano alantoin, ki se lahko iz telesa izloči z urinom.
English: Krystexxa was studied in two main studies involving 225 patients with severe tophaceous gout in whom allopurinol, a xanthine oxidase inhibitor, had previously failed to control their uric acid levels or could not be used due to side effects.
Slovenian: Zdravilo Krystexxa so proučili v dveh glavnih študijah, ki sta vključevali 225 bolnikov s hudim protinom s tofi, pri katerih alopurinol, zaviralec ksantin-oksidaze, ni bil uspešen pri nadzorovanju njihovih ravni sečne kisline ali ga ni bilo mogoče uporabljati zaradi neželenih učinkov.
English: The CHMP concluded that Krystexxa was highly effective in reducing uric acid levels.
Slovenian: CHMP je zaključil, da je bilo zdravilo Krystexxa zelo učinkovito pri zniževanju ravni sečne kisline.
English: Once levels of uric acid are below 6 mg/dl, this allows crystals in the joints to dissolve, slowly shrinking the tophi.
Slovenian: Ko ravni sečne kisline upadejo pod 6 mg/dl, kristali v sklepih razpadejo, tofi pa se počasi zmanjšajo.
English: In Krystexxa, uricase has been attached to a chemical, polyethylene glycol (PEG), which decreases the rate at which uricase is removed from the body, allowing its action to last longer.
Slovenian: Pri zdravilu Krystexxa je urikaza vezana na kemikalijo polietilenglikol (PEG), kar zmanjšuje hitrost, s katero se urikaza izloča iz telesa, in tako podaljšuje njeno delovanje.
English: The active substance in Krystexxa, pegloticase, contains an enzyme called uricase.
Slovenian: Zdravilna učinkovina zdravila Krystexxa, peglotikaza, vsebuje encim, imenovan urikaza.
English: Krystexxa is a medicine containing the active substance pegloticase.
Slovenian: Krystexxa je zdravilo, ki vsebuje zdravilno učinkovino peglotikaza.
English: Krystexxa given every two weeks resulted in fewer reactions to the infusion than when it was given every four weeks.
Slovenian: Zdravilo Krystexxa je povzročilo manj reakcij, če je bilo dano vsaka dva tedna, kot če je bilo dano vsake štiri tedne.
English: What is the risk associated with Krystexxa?
Slovenian: Kakšna tveganja so povezana z zdravilom Krystexxa?
English: For severely affected patients who cannot be treated effectively with conventional methods, the Committee considered that Krystexxa addressed an unmet need, since no alternative treatments are available.
Slovenian: Odbor je ocenil, da pri huje prizadetih bolnikih, pri katerih učinkovito zdravljenje z običajnimi metodami ni možno, zdravilo Krystexxa edino zadovoljuje njihove potrebe, saj alternativna zdravljenja niso na voljo.
English: Krystexxa was shown to be more effective than placebo in reducing uric acid levels.
Slovenian: Zdravilo Krystexxa se je pri zniževanju ravni sečne kisline izkazalo za učinkovitejše od placeba.
English: Why has Krystexxa been approved?
Slovenian: Zakaj je bilo zdravilo Krystexxa odobreno?
English: Krystexxa is only used in patients who cannot control their uric acid levels even at maximum doses of conventional medicines called xanthine oxidase inhibitors, or who are unable to use such medicines.
Slovenian: Zdravilo Krystexxa se uporablja le pri bolnikih, ki tudi pri jemanju največjih odmerkov običajnih zdravil, imenovanih zaviralci ksantin-oksidaze, ne morejo uravnavati ravni sečne kisline oziroma ki teh zdravil ne morejo jemati.
English: Krystexxa is given as an infusion into a vein every two weeks, at a recommended dose of 8 mg.
Slovenian: Zdravilo Krystexxa se daje z infundiranjem v veno vsaka dva tedna v priporočenem odmerku 8 mg. Infuzija se daje počasi v trajanju najmanj dveh ur.
English: For the full list of side effects reported with Krystexxa, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Krystexxa, glejte navodilo za uporabo.
English: For further information on the use of Krystexxa see the package leaflet.
Slovenian: Za podrobnejše informacije o uporabi zdravila Krystexxa glejte navodilo za uporabo.
English: What is Krystexxa used for?
Slovenian: Za kaj se zdravilo Krystexxa uporablja?
English: How does Krystexxa work?
Slovenian: Kako zdravilo Krystexxa deluje?
English: How has Krystexxa been studied?
Slovenian: Kako je bilo zdravilo Krystexxa raziskano?
English: How is Krystexxa used?
Slovenian: Kako se zdravilo Krystexxa uporablja?
English: What is Krystexxa?
Slovenian: Kaj je zdravilo Krystexxa?
English: Patients should not take other medicines that lower uric acid levels during Krystexxa treatment, so that the effect of Krystexxa can be clearly judged.
Slovenian: Zdravnik lahko z zdravljenjem z zdravilom Krystexxa nadaljuje le toliko časa, dokler to bolniku koristi, torej, dokler njegove ravni sečne kisline v krvi ostajajo nižje od 6 mg/dl. Bolniki med zdravljenjem z zdravilom Krystexxa ne smejo jemati drugih zdravil, ki znižujejo ravni sečne kisline, tako da je mogoče učinek zdravila Krystexxa jasno oceniti.
English: These measures will help protect the environment.
Slovenian: Taki ukrepi pomagajo varovati okolje
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 18 January 2016
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 18. januar 2016
English: Not known: frequency cannot be estimated from the available data
Slovenian: Neznana pogostnost: pogostnosti ni mogoče oceniti iz razpoložljivih podatkov
English: * Definition of frequency terms: Very common - ≥ 10 %; Common - > 5 % and < 10%.
Slovenian: * Definicija pogostnosti: Zelo pogosto - > 10 %; Pogosto - > 5 % in < 10 %.
English: Do not use this medicine if you notice any visible signs of deterioration.
Slovenian: Ne uporabljajte tega zdravila, če opazite vidne znake kvarjenja.
English: Wessling Hungary Kft. Fòti ùt 56., Budapest, 1047, Hungary
Slovenian: Wessling Hungary Kft. Fòti ùt 56., Budapest, 1047, Madžarska
English: Calculate the dose and the number of Pemetrexed Accord vials needed.
Slovenian: Izračunajte odmerek in število potrebnih vial zdravila Pemetreksed Accord.
English: Based on the planned date of your infusion of Pemetrexed Accord and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them.
Slovenian: Na podlagi načrtovanega datuma vaše infuzije zdravila Pemetreksed Accord in/ali glede na delovanje vaših ledvic vam mora zdravnik svetovati, katera zdravila lahko jemljete in kdaj jih lahko jemljete.
English: Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Slovenian: Pred začetkom jemanja tega zdravila, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
English: The total bilirubin should be  1.5 times upper limit of normal.
Slovenian: Celotni bilirubin mora biti  1,5-kratnika zgornje meje normalnih vrednosti.
English: 319, Pinner Road North Harrow Middlesex HA1 4HF United Kingdom
Slovenian: 319 Pinner Road North Harrow HA1 4HF
English: Driving and using machines Pemetrexed Accord may make you feel tired.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Pemetreksed Accord lahko povzroči, da se boste počutili utrujene.
English: Frequency estimate: Very common (≥ 1/10), Common ( 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000) and not known (cannot be estimated from available data).
Slovenian: Pogostnosti so določene kot: zelo pogosto (≥1/10), pogosto ( 1/100 do < 1/10), občasno (≥1/1000 do < 1/100), redko (≥1/10.000 do < 1/1000), zelo redko (<1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
English: The percentage of patients that received post study treatment was 64.3 % for pemetrexed and 71.7 % for placebo.
Slovenian: Odstotek bolnikov, ki so prejeli zdravljenje po študiji, je bil 64,3 % za pemetreksed in 71,7 % za placebo.
English: Instructions for use, handling and disposal.
Slovenian: Navodila za uporabo, ravnanje z zdravilom in odlaganje.
English: The European Medicines Agency has waived the obligation to submit the results of studies with pemetrexed in all subsets of the paediatric population in the granted indications (see Section 4.2).
Slovenian: Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij s pemetreksedom za vse skupine pediatrične populacije za odobrene indikacije (glejte poglavje 4.2).
English: Efficacy and safety were measured from the time of randomisation after completion of first line (induction) therapy.
Slovenian: Učinkovitost in varnost sta bili merjeni od časa randomizacije po zaključku zdravljenja prve izbire (indukcije).
English: Side effects with Pemetrexed Accord may include:
Slovenian: Neželeni učinki z zdravilom Pemetreksed Accord lahko vključujejo:
English: What Pemetrexed Accord is and what it is used for
Slovenian: Kaj je zdravilo Pemetreksed Accord in za kaj ga uporabljamo
English: Do not use Pemetrexed Accord - if you are allergic to pemetrexed or any of the other ingredients of this medicine (listed in section 6).
Slovenian: Ne uporabljajte zdravila Pemetreksed Accord: - če ste alergični na pemetreksed ali na katerokoli sestavino tega zdravila (navedeno v poglavju
English: Do not use this medicine after the expiry date which is stated on the label and carton after EXP.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pakiranju poleg oznake EXP.
English: Creatinine clearance should be  45 ml/min.
Slovenian: Očistek kreatinina mora biti  45 ml/min.
English: Your doctor will discuss with you the potential risk of taking Pemetrexed Accord during pregnancy.
Slovenian: S svojim zdravnikom se pogovorite o možnem tveganju pri prejemanju zdravila Pemetreksed Accord v času nosečnosti.
English: The 1 year and 2 year survival rates for patients on pemetrexed were 58 % and 32 % respectively, compared to 45 % and 21 % for patients on placebo.
Slovenian: Stopnji preživetja pri 1 in pri 2 letih pri bolnikih, ki so prejemali pemetreksed sta bili 58 % in 32 %, v primerjavi s 45 % in 21 % pri bolnikih, ki so prejemali placebo.
English: Pharmacotherapeutic group: antineoplastic agents, folic acid analogues, ATC code: L01BA04
Slovenian: Farmakoterapevtska skupina: antineoplastiki, analogi folne kisline, Oznaka ATC: L01BA04
English: Premedication regimen
Slovenian: Režim premedikacije
English: This medicine is for single use only.
Slovenian: To zdravilo je namenjeno samo enkratni uporabi.
English: If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.
Slovenian: Če niste prepričani, vprašajte zdravnika ali farmacevta, ali so katera od vaših zdravil NSAID-i.
English: What Pemetrexed Accord is and what it is used for What you need to know before you use Pemetrexed Accord How to use Pemetrexed Accord Possible side effects
Slovenian: Kaj je zdravilo Pemetreksed Accord in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Pemetreksed Accord Kako uporabljati zdravilo Pemetreksed Accord Možni neželeni učinki
English: What you need to know before you use Pemetrexed Accord
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Pemetreksed Accord
English: Pemetrexed Accord is a medicine used in the treatment of cancer.
Slovenian: Pemetreksed Accord je zdravilo, ki ga uporabljamo pri zdravljenju raka.
English: Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Pemetrexed Accord.
Slovenian: Pred vsako infuzijo vam bomo odvzeli vzorce krvi za vrednotenje delovanja vaših ledvic in jeter ter oceno, ali imate dovolj krvnih celic za prejemanje zdravila Pemetreksed Accord.
English: Alkaline phosphatase (AP), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) should be  3 times upper limit of normal.
Slovenian: Alkalna fosfataza (AF), aspartatna aminotransferaza (AST ali SGOT) in alaninska aminotransferaza (ALT ali SGPT) morajo biti  3-kratnik zgornje meje normalnih vrednosti.
English: ** In the pemetrexed/cisplatin arm, randomized and treated (N= 225) and fully supplemented (N = 167)
Slovenian: **V veji zdravljenja s pemetreksedom/cisplatinom, randomizirani in zdravljeni (N = 225) ter s popolnim dopolnjevanjem (N = 167).
English: Event*
Slovenian: Dogodek*
English: Upon recovery patients should be retreated using the guidelines in Tables 1, 2 and 3, which are applicable for Pemetrexed Accord used as a single agent or in combination with cisplatin.
Slovenian: Po okrevanju bolnike ponovno zdravimo z uporabo smernic v Preglednicah 1, 2 in 3, ki veljajo za zdravilo Pemetreksed Accord, če ga uporabljamo kot edino učinkovino ali v kombinaciji s cisplatinom.
English: Interactions common to all cytotoxics:
Slovenian: Medsebojna delovanja, ki so skupna vsem citotoksičnim zdravilom:
English: The recommended dose of Pemetrexed Accord is 500 milligrams for every square metre of your body's surface area.
Slovenian: Priporočeni odmerek zdravila Pemetreksed Accord je 500 miligramov za vsak kvadratni meter površine vašega telesa.
English: A total of 213 patients (48.3 %) completed ≥ 6 cycles and a total of 103 patients (23.4 %) completed ≥ 10 cycles of treatment with pemetrexed.
Slovenian: Skupno 213 bolnikov (48,3 %) je zaključilo ≥ 6 ciklov in skupno 103 bolniki (23,4 %) so zaključili ≥ 10 ciklov zdravljenja s pemetreksedom.
English: In clinical studies, patients with creatinine clearance of  45 ml/min required no dose adjustments other than those recommended for all patients.
Slovenian: V kliničnih študijah bolniki z očistkom kreatinina  45 ml/min niso potrebovali prilagajanja odmerkov, razen tistih prilagoditev, ki jih priporočamo za vse bolnike.
English: Of the randomised patients, 44.9 % had a complete/partial response and 51.9 % had a response of stable disease to pemetrexed plus cisplatin induction.
Slovenian: Izmed naključno izbranih bolnikov jih je 44,9 % doseglo popoln/delen odziv in 51,9 % jih je doseglo odziv stabilne bolezni na pemetreksed in indukcijsko zdravilo cisplatina.
English: At the time of this final survival analysis, 28.7 % of patients were alive or lost to follow up on the pemetrexed arm versus 21.7 % on the placebo arm.
Slovenian: V času te končne analize preživetja je bilo živih ali ni bilo na voljo za nadaljnje spremljanje 28,7 % bolnikov v kraku s pemetreksedom v primerjavi z 21,7 % v kraku s placebom.
English: Creatinine elevation Creatinine clearance decreased**
Slovenian: Zelo pogosto Povišan kreatinin Znižan očistek kreatinina**